Connected Drug Delivery Devices Market Size & Growth Forecast 2026–2035, By Segments (Application, Product Type, Route of Administration), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Connected Drug Delivery Devices Market size stood at USD 8.39 Billion in 2025 and is predicted to grow at a 22.7% CAGR from 2026 to 2035, reaching USD 64.89 Billion by 2035. The industry revenue for 2026 is estimated at USD 10.12 billion.

• Base Year Value (2025): USD 8.39 Billion
• CAGR (2026-2035): 22.7%
• Forecast Year Value (2035): USD 64.89 Billion
• Historical Data Period: 2022-2025
• Largest Region: North America
• Forecast Period: 2026-2035

Connected Drug Delivery Devices Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America leads the market through strong adoption of digital healthcare, established reimbursement systems, and widespread integration of connected therapies into chronic disease management workflows.
  • Asia Pacific is forecast to grow at a 24.97% CAGR as digital health adoption expands and healthcare providers increasingly deploy connected solutions for medication tracking and remote patient management.

• Segment Momentum:

  • Diabetes Management accounted for 32.4% of the market in 2025, driven by the routine need for insulin delivery, dose tracking, adherence monitoring, and continuous patient engagement.
  • Integrated Devices are expanding fastest because they combine drug delivery and connectivity in one system, simplifying treatment while enabling consistent data transmission and easier integration into routine care workflows.

• Market Expansion Drivers:

  • Rising demand for remote patient monitoring accelerating adoption of connected medication devices.
  • Increasing focus on medication adherence driving integration of smart dosing and reminder technologies.
  • Strategic collaborations in digital diabetes management expanding connected drug delivery ecosystems.

• Leading Market Participants:

  Key players in the connected drug delivery devices market include Medtronic plc (Ireland), Teva Pharmaceutical Industries Ltd. (Israel), Koninklijke Philips N.V. (Netherlands), Ypsomed Holding AG (Switzerland), Biocorp Production S.A. (France), Propeller Health (United States), Adherium Limited (New Zealand), Amiko Digital Health Ltd. (Switzerland), Phillips-Medisize LLC (United States), Cohero Health Inc. (United States).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2025 Market Size: USD 8.39 Billion
  • Projected Market Size: USD 64.89 Billion by 2035
  • Growth Forecasts: 22.7% CAGR (2026-2035)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Diabetes Management (Application) | Integrated Devices (Product Type) | Inhalational (Route of Administration)
  • Emerging Opportunity Segment: Diabetes Management (Application) | Integrated Devices (Product Type) | Inhalational (Route of Administration)

Market Growth Drivers and Industry Trends

Rising demand for remote patient monitoring accelerating adoption of connected medication devices

As care delivery shifts toward home-based management of chronic conditions, providers are placing greater value on devices that transmit dosing activity, usage patterns, and treatment status without requiring in-person follow-up. In the connected drug delivery devices market, this is driving demand for injectors, inhalers, and infusion-related platforms that can feed data into remote monitoring workflows, allowing clinicians to identify missed doses, improper use, or early signs of therapy disruption. Procurement decisions increasingly favor products that combine drug administration with digital visibility, since remote oversight improves continuity of care while helping health systems manage larger patient populations outside traditional settings.

Increasing focus on medication adherence driving integration of smart dosing and reminder technologies

Payers, providers, and pharmaceutical companies are giving more attention to whether patients follow prescribed regimens, especially in long-term therapies where missed or mistimed doses weaken outcomes and increase downstream costs. That pressure is influencing market adoption in the connected drug delivery devices market by pushing manufacturers to embed reminder alerts, dose logging, usage confirmation, and app-linked adherence support directly into delivery systems. The commercial appeal of these features comes from their practical role in reducing patient drop-off and generating actionable adherence data, which makes connected devices more attractive not only as administration tools but also as platforms for ongoing therapy management.

Strategic collaborations in digital diabetes management expanding connected drug delivery ecosystems

Partnerships between device makers, digital health companies, software developers, and diabetes care stakeholders are reshaping how products are positioned and used in routine treatment. In the connected drug delivery devices market, these collaborations are supporting market development by linking insulin delivery hardware with glucose data platforms, companion apps, and decision-support tools, creating more integrated care experiences than standalone devices can offer. This ecosystem approach influences purchasing and adoption because healthcare providers and users increasingly prefer solutions that fit into a broader diabetes management workflow, while manufacturers gain faster access to interoperability capabilities and established user networks through collaboration rather than internal development alone.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising demand for remote patient monitoring accelerating adoption of connected medication devices	2.00%	High	North America, Europe	High	Near Term
Increasing focus on medication adherence driving integration of smart dosing and reminder technologies	1.90%	High	North America, Asia Pacific	High	Mid Term
Strategic collaborations in digital diabetes management expanding connected drug delivery ecosystems	1.60%	Moderate	North America, Europe	Emerging	Long Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held the largest regional market share in 2025 for the connected drug delivery devices market, supported by broad uptake of digitally enabled care models, established reimbursement structures, and stronger integration of connected therapies into routine chronic disease management. The region’s leadership is aided by higher adoption of insulin delivery, remote monitoring, and app-linked adherence tools across provider networks that are already equipped to use patient-generated treatment data in everyday care decisions. This operating environment helps device manufacturers and healthcare systems move connected products beyond pilot use into regular clinical workflows.

Asia Pacific is projected to expand at a 24.97% CAGR over the forecast period, with growth in the connected drug delivery devices market being propelled by faster digital health adoption and rising deployment of connected care solutions across large patient populations. Demand is accelerating as healthcare providers and patients increasingly use mobile-first health platforms that can support medication tracking, adherence monitoring, and remote follow-up in practical, scalable ways. As access to connected technologies broadens across the region, adoption is being driven by the need to manage treatment delivery more efficiently in high-volume care settings.

Key Country Insights

United States

Digital Therapeutics Integration

The U.S. prioritizes connected drug delivery devices that integrate with remote patient monitoring platforms and electronic health records. Healthcare providers and manufacturers emphasize adherence tracking, real-world data collection, and value-based care initiatives across chronic disease management.

Japan

Aging Care Connectivity

Japan advances connected drug delivery devices to improve medication adherence among its aging population. Companies prioritize compact, user-friendly systems with remote monitoring functions that complement home-based care and long-term disease management programs.

South Korea

Smart Health Ecosystem

South Korea integrates connected drug delivery devices with advanced digital health infrastructure and mobile healthcare platforms. Local innovation focuses on connected therapies, real-time patient engagement, and secure data sharing to improve treatment continuity.

Germany

Precision Care Adoption

Germany emphasizes connected drug delivery devices that support structured disease management and secure health data exchange. Manufacturers focus on interoperable solutions aligned with digital healthcare initiatives while providers seek reliable patient adherence and therapy monitoring capabilities.

France

Patient Monitoring Focus

France supports connected drug delivery devices through initiatives that enhance chronic disease monitoring and coordinated patient care. Healthcare stakeholders increasingly value solutions that improve treatment compliance while fitting established clinical workflows.

Italy

Home Therapy Support

Italy is expanding the use of connected drug delivery devices to strengthen home-based treatment and outpatient care. Device suppliers emphasize intuitive operation, remote follow-up, and improved medication adherence for patients managing long-term conditions.

Segment Leadership and Growth Trends

  Application Segment Analysis: Diabetes Management (Largest & Fastest-Growing Segment)

Diabetes Management held a 32.4% share of the connected drug delivery devices market in 2025, reflecting its established lead as the most commercially active application area and its continued growth momentum. This position is sustained by the routine, high-frequency nature of insulin administration and dose tracking, which creates a clear need for connected devices that support adherence, monitoring, and day-to-day treatment adjustments. The same practical care requirements are also driving faster expansion in this segment of the connected drug delivery devices market, as diabetes therapy depends heavily on consistent data capture and user engagement in a way that is more embedded in regular patient management than many other applications.

Product Type Segment Analysis: Integrated Devices (Largest & Fastest-Growing Segment)

Within the connected drug delivery devices market, Integrated Devices represented the leading product type in 2025, holding the largest share and continuing to expand at the fastest pace. Their market strength comes from the operational advantage of combining drug delivery and connectivity in a single system, which simplifies usage, reduces reliance on separate add-on components, and supports more consistent data transmission during routine treatment. That same built-in convenience is also accelerating adoption in the connected drug delivery devices market, as healthcare providers and users increasingly favor solutions that fit directly into existing administration workflows without added setup complexity.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Application	Asthma, COPD, Diabetes Management, Others	Diabetes Management	Diabetes Management
Product Type	Standalone Components & Software, Integrated Devices	Integrated Devices	Integrated Devices
Route of Administration	Parenteral, Inhalational	Inhalational	Inhalational

Competitive Landscape and Market Positioning

Top players in the connected drug delivery devices market:

1. Medtronic plc (Ireland)

2. Teva Pharmaceutical Industries Ltd. (Israel)

3. Koninklijke Philips N.V. (Netherlands)

4. Ypsomed Holding AG (Switzerland)

5. Biocorp Production S.A. (France)

6. Propeller Health (United States)

7. Adherium Limited (New Zealand)

8. Amiko Digital Health Ltd. (Switzerland)

9. Phillips-Medisize LLC (United States)

10. Cohero Health Inc. (United States)

The connected drug delivery devices market is evolving through deeper integration of digital monitoring and patient-centric delivery systems. Growing emphasis on treatment adherence and remote tracking is accelerating smart healthcare connectivity. Continuous development efforts are focused on improving usability while strengthening real-time data-driven treatment support.

Industry Development/News

Company Name	Date	Key Development
Nemera	Sep-22	Nemera inaugurated a new facility in Lyon, France, intended to serve as its European headquarters and innovation center. The site strengthens the company’s R&D and industrial capabilities in drug delivery device development, supporting broader commercialization of connected and advanced delivery systems through enhanced engineering, prototyping, and operational integration in Europe.
Enable Injections	May-25	Enable Injections received EU MDR CE mark approval for its enFuse Syringe Transfer System, enabling commercialization across European markets. The certification supports regulatory expansion of its large-volume subcutaneous delivery platform, strengthening the company’s position in advanced drug administration technologies and facilitating broader adoption of connected and patient-centric injectable delivery solutions.
Supernus Pharmaceuticals	Feb-25	Supernus Pharmaceuticals received FDA approval for ONAPGO, a subcutaneous apomorphine infusion device for Parkinson’s motor fluctuations. The approval marks a significant commercialization milestone, expanding treatment options in neurological drug delivery and strengthening Supernus’s presence in device-enabled therapeutic solutions for chronic neurodegenerative disease management.
Gerresheimer	Dec-24	Gerresheimer obtained FDA tentative approval for Lasix ONYU, a home-use furosemide micropump designed for congestive heart failure management. The development enhances Gerresheimer’s position in digitally enabled drug delivery systems, supporting the shift toward at-home infusion therapies and expanding its portfolio of connected and patient-managed drug delivery solutions.
Medtronic	Nov-24	Medtronic received FDA clearance for its InPen app featuring missed-meal detection, integrated with its CGM ecosystem. The update strengthens Medtronic’s digital diabetes management portfolio by enhancing data-driven insulin dosing support, reinforcing its position in connected drug delivery ecosystems that integrate devices, sensors, and software platforms for chronic disease management.
Aptar Pharma	Jan-20	Aptar Pharma partnered with Lupin Limited to launch ADHERO, India’s first connected metered-dose inhaler add-on device. The solution enables real-time tracking of inhaler usage for respiratory patients, strengthening adherence monitoring capabilities and expanding Aptar Pharma’s presence in connected respiratory drug delivery solutions within emerging markets.
Propeller Health	May-20	Propeller Health received FDA 510(k) clearance to connect Symbicort inhaler users to its digital health platform. The clearance enabled expanded integration of inhaled therapies with digital monitoring systems, strengthening Propeller’s role in connected respiratory care and improving patient adherence and outcome tracking in chronic respiratory disease management.